advertisement
Abstract #99339 Published in IGR 22-4
Impact of Primary Needling on the XEN Implant Clinical Outcomes: A Real-Life Retrospective Study
Buenasmañanas-Maeso M; Buenasmañanas-Maeso M; Perucho-Martínez S; Perucho-Martínez S; Monja-Alarcón N; Monja-Alarcón N; Toledano-Fernández NClinical Ophthalmology 2022; 16: 935-946
PURPOSE: To assess the effectiveness and safety of primary-needling in eyes who underwent a XEN45 implant. METHODS: Retrospective and single center study. Consecutive patients with early-to-moderate open-angle glaucoma (OAG) or ocular hypertension, who underwent XEN45 surgery, either alone or combined with phacoemulsification, and had at least a valid 12-month post-operative visit, were included in the study. Primary needling was performed by using a 30-gauge needle without viscoelastic. Subjects were divided in two groups: Eyes who underwent XEN+primary-needling (needling) and those who underwent XEN without primary-needling (no-needling). The primary end-point was the mean change in IOP from baseline to the last follow-up visit. RESULTS: Sixty-three eyes, 19 (30.2%) in the needling group and 44 (69.8%) in the no-needling one, were included in the study. There were not significant differences in mean IOP lowering between needling and no-needling groups at month-12 (mean difference -2.5±5.3 mm Hg, p=0.0926). No significant differences in mean reduction of ocular-hypotensive medications were observed between needling and no-needling groups, p=0.8690. At month-12, 50 (80.6%) had blebs considered as functioning, with no difference between groups, p = 0.5631. At month-12, 59 (93.7%) eyes were classified as success, with no significant differences between needling (17/19) and no-needling (42/44) groups, p=0.3754. Secondary needling was performed in 8 (12.7%) eyes, without differences between groups (p=0.6333). CONCLUSION: Primary needling, at the time of surgery, was a safe procedure in OAG patients who underwent a XEN implant, although it was not associated with a lower postoperative IOP or less ocular hypotensive medications.
Ophthalmology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
Full article